LSE:AZN
LSE:AZNPharmaceuticals

Taking Stock of AstraZeneca (LSE:AZN): Is Its 31% One-Year Return Now Fully Valued?

AstraZeneca (LSE:AZN) has quietly ground out solid gains over the past year, and today’s move is less about a flashy headline and more about how that trend stacks up against its fundamentals. See our latest analysis for AstraZeneca. The latest dip in AstraZeneca’s £135.92 share price comes after a strong run, with a 90 day share price return of 7.45% contributing to a 1 year total shareholder return of 31.08%, suggesting momentum is still broadly constructive. If AstraZeneca’s steady progress...
AIM:PMI
AIM:PMICapital Markets

UK Penny Stocks To Consider In January 2026

The UK market has recently faced challenges, with the FTSE 100 and FTSE 250 indices experiencing declines due to weaker trade data from China, highlighting global economic interdependencies. Despite these broader market pressures, penny stocks remain an intriguing investment area for those seeking growth opportunities in smaller or newer companies. While the term 'penny stocks' may seem outdated, these investments can still offer potential when backed by strong financial health and a...
LSE:MARS
LSE:MARSHospitality

3 Undervalued Small Caps In Global With Insider Buying

As global markets navigate a complex landscape marked by record highs in major indices and fluctuating consumer confidence, small-cap stocks have shown mixed performance with the Russell 2000 Index inching up slightly. In this environment, identifying promising small-cap opportunities often involves looking for companies with strong fundamentals and insider buying activity, which can signal potential confidence from those closest to the business.